X4 Institutional Influx
Perceptive Advisors Increases X4 Pharmaceuticals Holdings Amid Mixed Analyst Views
Key Points
Beyond Perceptive Advisors’ stake increase, other large investors also expanded positions in X4 Pharmaceuticals: for example, Bain Capital Life Sciences Investors LLC increased its holding by 227% in the fourth quarter to 7,967,454 shares valued at about $31.87 million.
Analyst actions for X4 Pharmaceuticals included both a downgrade and an upgrade: Weiss Ratings cut the stock from “sell (d-)” to “sell (e+)” (June 4), while Wall Street Zen upgraded it from “sell” to “hold” (date not fully shown in the excerpt).
Other funds also took positions in X4 Pharmaceuticals during the fourth quarter, including Empery Asset Management LP (new position valued at about $35.8 million) and Kalehua Capital Management LLC (new position valued at about $14.9 million).
For Caris Life Sciences, analyst coverage included a downgrade of sorts: Wolfe Research cut Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research report (the excerpt provides the direction of the change).
Brokerage targets for Caris Life Sciences moved lower: BTIG Research reduced its price target from $38 to $32 (rating not specified in the excerpt), adding to the mixed sentiment around CAI.
Perceptive Advisors LLC has built a 7.2% stake in X4 Pharmaceuticals, buying roughly 6.3 million shares worth about $25.3 million, according to MarketBeat. The New York healthcare hedge fund is betting on a small biotech that just won its first drug approvals in both the US and Europe.
The firm, run by Joseph Edelman and CIO Adam Stone, also added to a smaller position in newly public Caris Life Sciences, holding about 1.14 million shares worth $30.7 million, per Fintel.
Bain Capital and Others Pile Into X4 Pharmaceuticals
Perceptive is not alone in loading up on X4. Bain Capital Life Sciences Investors LLC raised its holding by 227% in the fourth quarter to 7,967,454 shares valued at about $31.87 million, according to WallStreetZen. That gives Bain roughly 8.45% of the company. Empery Asset Management LP opened a brand-new position worth about $35.8 million, while Kalehua Capital Management LLC took a new stake worth about $14.9 million.
Institutions now own about 92% of X4's shares outstanding, per WallStreetZen. That leaves almost no room for retail investors to influence the company. X4 CEO Dr. Paula Ragan has described the company as moving into a "fully integrated biopharmaceutical company" phase after winning approvals in the US in April 2024 and in the EU in April 2026 for its drug XOLREMDI, the first-ever treatment for WHIM syndrome.
XOLREMDI Approval Drives Optimism Despite Share Dilution Concerns
X4's lead drug, mavorixafor, is a CXCR4 antagonist — a medicine that targets a specific protein to treat a rare immune disease called WHIM syndrome. The US FDA approved it in April 2024. The European Commission followed in April 2026. X4's European partner Norgine could trigger up to €226 million in milestone payments, which would extend the company's cash runway, according to StockTitan.
But not everyone is bullish. Weiss Ratings cut X4 from "Sell (d-)" to "Sell (e+)" on June 4, citing the stock's high volatility and heavy share dilution. Shares outstanding grew by 1,529% over the past year to fund the commercial launch, per Simply Wall St. Wall Street Zen countered with an upgrade from "Sell" to "Hold" on June 15, suggesting sentiment is at least stabilizing.
Caris Life Sciences Faces Analyst Downgrades After IPO Pop
Caris Life Sciences debuted on Nasdaq on June 18, 2025, at $21 per share, raising roughly $494 million in an upsized IPO, according to Simpson Thacher & Bartlett. The company, led by founder and CEO David D. Halbert, uses a database of over 1 million genomic profiles to guide cancer treatment decisions. Revenue grew 79% year-over-year in Q1 2026 to $216.2 million, per TIKR.
Despite the growth, analysts are turning cautious. On June 2, Wolfe Research analyst Mike Polark downgraded Caris from "Outperform" to "Peer Perform," citing competitive pressures in the tissue selection market, per TipRanks. BTIG Research's Mark Massaro cut his price target from $38 to $32 on May 8, though he kept a "Buy" rating, according to Quiver Quantitative. Caris responded on June 8 by authorizing a $100 million share repurchase program to support its stock price near its 52-week low.
Institutions See Long-Term Value Where Short-Term Models See Risk
The divide between institutional and quantitative views is sharp. Weiss Ratings penalizes X4 for negative earnings and a high beta of 3.85 — meaning the stock swings far more than the broader market. Perceptive and Bain Capital take the opposite view. They are betting that Phase 3 trial data for mavorixafor in chronic neutropenia, expected in 2026, could unlock a much larger market than WHIM syndrome alone, per BiotechEdge.
For Caris, the gap is equally wide. TIKR's financial models project a price of $159 by 2030 — a 560% gain from current levels. But Wolfe Research's near-term "Peer Perform" rating suggests the stock may lag rivals before that upside materializes. Perceptive's 0.4% stake worth $30.7 million signals a measured, not aggressive, bet on the AI-driven diagnostics firm for now, per MarketBeat.
Sentiment
Mostly PositivePublishers
20
Articles
13
Reach
33
